Results from a Phase 3b trial comparing secukinumab (Cosentyx) with adalimumab for the treatment of active psoriatic arthritis were published on 2020-01-01. The EXCEED study was a double-blind, parallel-group, randomized, active-controlled trial designed to assess the comparative efficacy of these two biologic therapies in patients with active psoriatic arthritis.
Background
Secukinumab (Cosentyx) is a biologic medication used in the treatment of various inflammatory conditions, including psoriatic arthritis. It targets interleukin-17A (IL-17A), a cytokine involved in inflammation and immune responses. Adalimumab is another widely used biologic, often employed as a standard treatment for psoriatic arthritis, among other autoimmune diseases. The EXCEED trial aimed to provide direct comparative data between these two established treatments for active psoriatic arthritis.
Trial design
The EXCEED study was a Phase 3b, double-blind, parallel-group, randomized, active-controlled trial. It compared secukinumab against adalimumab in patients diagnosed with active psoriatic arthritis. The trial's design focused on evaluating the efficacy of secukinumab relative to adalimumab, which served as the active comparator. This type of head-to-head comparison is crucial for clinicians when making informed treatment decisions for their patients.
What this means
The publication of the EXCEED trial results provides important comparative data for clinicians treating patients with active psoriatic arthritis. By directly comparing secukinumab with adalimumab, the study contributes to the understanding of the relative efficacy profiles of these two biologic agents. This information can help guide treatment selection, allowing healthcare providers to consider the specific benefits and characteristics of each drug in the context of individual patient needs and disease presentation. The trial's findings are significant for optimizing therapeutic strategies in psoriatic arthritis management.
Source
The information regarding this pivotal trial publication was obtained from PubMed. The article, titled "Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial", was published on 2020-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.